United BioSource Corp. has acquired drug safety software maker Gigamoto Technology Partners. The acquisition, says UBC, is part of a strategy to build integrated capabilities in risk management and drug safety.
UBC's global drug safety and risk management services include risk evaluation and mitigation programs. Gigamoto--UBC's second purchase this year in support of its objective to expand globally--provides additional scale and commercial Internet site functionality to UBC's offerings, according to an announcement.
The Gigamoto software powers several complex risk management programs, including the FDA-mandated iPLEDGE program. iPLEDGE is a computer-based distribution center that monitors pregnancy in women taking the acne medication Accutane, (isotretinoin), known to cause birth defects. iPLEDGE was mandated by the FDA in 2006. The risk-management system has registered more than 40,000 pharmacies, 16,000 prescribers and 300,000 patients.
- read the announcement